TVAX Biomedical plans killer $40M IPO to fund PhIII vaccine for naive astrocytoma
This article was originally published in Scrip
Executive Summary
TVAX Biomedical, a US startup focused on targeted cell-based immunotherapies for the treatment of cancer, has filed for a $40 million initial public offering.